Amarin Corp Plc (AMRN)

[couldbebetter]

When one considers the annual cost of the PCKS-9 ($15,000.00) and the new Novartis anti-inflammatory ($60,000.00) it would be logical to assume that insurance companies would rather have patients on Vascepa at a fraction of the cost. Yet, the highest Wall Street estimate I have seen for Vascepa says max sales of $2 billion a year. I can't understand how they come to such low numbers for Vascepa and yet Mathew Herper (Forbes) calls the Novartis drug a $60 billion market opportunity with 10% would give the Novartis drug $6 billion in sales. So AMRN is projected what? <2% of the 40 million statin users in the US? And NVS at a $60,000.00 cost can have 10% of the US/EUR market for their drug. My point here is to show that Wall Street has no idea of what the potential for Vascepa could be. If Vascepa were to have 10% of the 40 million statin users in the US in 2020 that would be 4 million patients X $2000.00 each = $8 billion in revenues. At 4 X revenues the market cap would be $32 billion. Let's throw in future dilution of 250 million shares and the price would work out to over $50.00 a share. (Sorry for the long post but I'm on my second pot of cofee today.)